TY - JOUR
T1 - Association Between Diarrhea Duration and Severity and Probiotic Efficacy in Children With Acute Gastroenteritis
AU - Pediatric Emergency Care Applied Research Network and Pediatric Emergency Research Canada
AU - Schnadower, David
AU - O'Connell, Karen J.
AU - VanBuren, John M.
AU - Vance, Cheryl
AU - Tarr, Phillip I.
AU - Schuh, Suzanne
AU - Hurley, Katrina
AU - Rogers, Alexander J.
AU - Poonai, Naveen
AU - Roskind, Cindy G.
AU - Bhatt, Seema R.
AU - Gouin, Serge
AU - Mahajan, Prashant
AU - Olsen, Cody S.
AU - Powell, Elizabeth C.
AU - Farion, Ken
AU - Sapien, Robert E.
AU - Chun, Thomas H.
AU - Freedman, Stephen B.
N1 - Publisher Copyright:
© 2021 by The American College of Gastroenterology.
PY - 2021/7/1
Y1 - 2021/7/1
N2 - INTRODUCTION:It is unclear whether the alleged efficacy of probiotics in childhood acute gastroenteritis depends on the duration and severity of symptoms before treatment.METHODS:Preplanned secondary analysis of 2 randomized placebo-controlled trials in children 3-48 months of age was conducted in 16 emergency departments in North America evaluating the efficacy of 2 probiotic products (Lactobacillus rhamnosus GG and a combination probiotic: L. rhamnosus and L. helveticus). Participants were categorized in severity groups according to the duration (<24, 24-<72, and ≥72 hours) and the frequency of diarrhea episodes in the 24 hours (≤3, 4-5, and ≥6) before presentation. We used regression models to assess the interaction between pretreatment diarrhea severity groups and treatment arm (probiotic or placebo) in the presence of moderate-to-severe gastroenteritis (Modified Vesikari Scale score ≥9). Secondary outcomes included diarrhea frequency and duration, unscheduled healthcare provider visits, and hospitalization.RESULTS:A total of 1,770 children were included, and 882 (50%) received a probiotic. The development of moderate-to-severe gastroenteritis symptoms after the initiation of treatment did not differ between groups (probiotic - 18.4% [162/882] vs placebo - 18.3% [162/888]; risk ratio 1.00; 95% confidence interval 0.87, 1.16; P = 0.95). There was no evidence of interaction between baseline severity and treatment (P = 0.61) for the primary or any of the secondary outcomes: diarrhea duration (P = 0.88), maximum diarrheal episodes in a 24-hour period (P = 0.87), unscheduled healthcare visits (P = 0.21), and hospitalization (P = 0.87).DISCUSSION:In children 3-48 months with acute gastroenteritis, the lack of effect of probiotics is not explained by the duration of symptoms or frequency of diarrheal episodes before presentation.
AB - INTRODUCTION:It is unclear whether the alleged efficacy of probiotics in childhood acute gastroenteritis depends on the duration and severity of symptoms before treatment.METHODS:Preplanned secondary analysis of 2 randomized placebo-controlled trials in children 3-48 months of age was conducted in 16 emergency departments in North America evaluating the efficacy of 2 probiotic products (Lactobacillus rhamnosus GG and a combination probiotic: L. rhamnosus and L. helveticus). Participants were categorized in severity groups according to the duration (<24, 24-<72, and ≥72 hours) and the frequency of diarrhea episodes in the 24 hours (≤3, 4-5, and ≥6) before presentation. We used regression models to assess the interaction between pretreatment diarrhea severity groups and treatment arm (probiotic or placebo) in the presence of moderate-to-severe gastroenteritis (Modified Vesikari Scale score ≥9). Secondary outcomes included diarrhea frequency and duration, unscheduled healthcare provider visits, and hospitalization.RESULTS:A total of 1,770 children were included, and 882 (50%) received a probiotic. The development of moderate-to-severe gastroenteritis symptoms after the initiation of treatment did not differ between groups (probiotic - 18.4% [162/882] vs placebo - 18.3% [162/888]; risk ratio 1.00; 95% confidence interval 0.87, 1.16; P = 0.95). There was no evidence of interaction between baseline severity and treatment (P = 0.61) for the primary or any of the secondary outcomes: diarrhea duration (P = 0.88), maximum diarrheal episodes in a 24-hour period (P = 0.87), unscheduled healthcare visits (P = 0.21), and hospitalization (P = 0.87).DISCUSSION:In children 3-48 months with acute gastroenteritis, the lack of effect of probiotics is not explained by the duration of symptoms or frequency of diarrheal episodes before presentation.
UR - http://www.scopus.com/inward/record.url?scp=85109765102&partnerID=8YFLogxK
U2 - 10.14309/ajg.0000000000001295
DO - 10.14309/ajg.0000000000001295
M3 - Article
C2 - 34183579
AN - SCOPUS:85109765102
SN - 0002-9270
VL - 116
SP - 1523
EP - 1532
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 7
ER -